BRADLEY PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS
(UNAUDITED)
Three Months Ended Six Months Ended
June 30, June 30,
---------------------- --------------------
2000 1999 2000 1999
---------------------- --------------------
Net sales $ 4,091,755 $ 4,287,462 $ 6,889,047 $ 9,415,932
Cost of sales 976,402 1,345,770 1,854,367 2,654,997
---------- ---------- ---------- ----------
3,115,353 2,941,692 5,034,680 6,760,935
Selling, general and
administrative expenses 2,508,007 2,432,459 5,408,144 4,970,643
Depreciation and
amortization 237,445 316,044 482,077 639,050
Interest expense - net 54,491 47,346 111,938 122,074
Loss due to impairment of
asset - - 3,897,000 -
---------- ---------- ---------- ----------
2,799,943 2,795,849 9,899,159 5,731,767
---------- ---------- ---------- ----------
Income (loss) before
income taxes 315,410 145,843 (4,864,479) 1,029,168
Income tax expense
(benefit) 123,000 53,000 (377,000) 380,000
---------- ---------- ---------- ---------
Net income (loss) $ 192,410 $ 92,843 $(4,487,479) $ 649,168
========== ========== ========== =========
Net income (loss)
per common share
Basic & Diluted $ 0.02 $ 0.01 $ (0.57) $ 0.08
========== ========== ========== =========
Weighted average number
of common shares
Basic 7,910,000 7,970,000 7,900,000 8,050,000
========== ========== ========== ==========
Diluted 8,020,000 8,070,000 7,900,000 8,130,000
========== ========== ========== ==========
See Notes to Condensed Consolidated Financial Statements
4
